Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Green Light For Samsung Bioepis’s Biosimilar Etanercept

This article was originally published in PharmAsia News

Executive Summary

Within just three and a half years since its establishment, Samsung Bioepis has received its first regulatory approval for a biosimilar, meaning the Samsung Group affiliate is now set to release its version of Amgen’s Enbrel (etanercept) in South Korea late this year or early next. It will be the fourth locally developed biosimilar to hit the domestic market and is expected to be priced at about a 30% discount.

Advertisement

Related Content

Merck’s Revised Biosimilar Strategy Poised To Deliver

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC089210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel